[{"quiz_id": "20251219T221819110Z_deepseek-v3.2_seed133", "question_id": "20251219T221819110Z_deepseek-v3.2_seed133-001", "question": "A 52-year-old man with primary sclerosing cholangitis and ulcerative colitis maintained on vedolizumab presents with progressive jaundice, pruritus, and weight loss over 3 months. MRCP shows a dominant stricture at the hepatic hilum with intrahepatic ductal dilation. CA 19-9 is 180 U/mL. Brush cytology from ERCP is suspicious but not diagnostic for malignancy. PET-CT shows FDG avidity at the stricture with standardized uptake value (SUV) max of 6.2. Which of the following is the most appropriate next step in management?", "options": ["Proceed directly to liver transplantation without biopsy confirmation given high suspicion for cholangiocarcinoma in PSC", "Perform endoscopic ultrasound with fine-needle aspiration of the hilar mass", "Initiate neoadjuvant chemoradiation followed by liver transplantation per Mayo Clinic protocol", "Repeat ERCP with cholangioscopy and targeted biopsies of the suspicious area", "Treat as benign dominant stricture with serial stenting and repeat CA 19-9 in 3 months"], "answer": "C", "answer_index": 2, "explanation": "In patients with PSC and suspected hilar cholangiocarcinoma, the Mayo Clinic protocol for neoadjuvant chemoradiation followed by liver transplantation requires strict diagnostic criteria including biopsy confirmation or strongly suggestive findings (CA 19-9 >100 U/mL, malignant-appearing stricture on imaging). PET SUV >5.0 with suspicious cytology meets criteria for protocol enrollment. Direct transplantation without protocol adherence risks transplanting unrecognized metastatic disease. Cholangioscopy and EUS-FNA have higher risks of peritoneal seeding in potentially resectable/transplantable cases.", "generator_model": "deepseek-v3.2", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem provides a classic PSC scenario with a dominant hilar stricture, CA 19‑9 >100 U/mL, suspicious brush cytology, and a high‑risk PET SUV (6.2). These findings satisfy the Mayo Clinic transplant‑protocol entry criteria (CA 19‑9 >100 U/mL plus suspicious cytology), making neoadjuvant chemoradiation followed by transplant the most appropriate next step. Direct transplant (A) is unsafe without protocol‑mandated staging; EUS‑FNA (B) is not indicated for hilar lesions and carries seeding risk; repeat ERCP with cholangioscopy (D) could obtain a tissue diagnosis but is less appropriate when the patient already meets protocol criteria and any instrumentation may risk peritoneal seeding; serial stenting (E) ignores malignancy. The only logical flaw is the answer explanation’s claim that PET SUV >5.0 alone fulfills protocol criteria, which is not part of the formal guidelines; this overstatement is a minor medical accuracy issue. A single clarifying addition to the stem—stating that the patient has been deemed a transplant candidate—would eliminate any ambiguity and make choice C unequivocally the best answer.\",\n\"medical_accuracy_score\":   \t\"3\",\n\"logical_validity\": true,\n\"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem provides a classic PSC scenario with a dominant hilar stricture, CA 19‑9 >100 U/mL, suspicious brush cytology, and a high‑risk PET SUV (6.2). These findings satisfy the Mayo Clinic transplant‑protocol entry criteria (CA 19‑9 >100 U/mL plus suspicious cytology), making neoadjuvant chemoradiation followed by transplant the most appropriate next step. Direct transplant (A) is unsafe without protocol‑mandated staging; EUS‑FNA (B) is not indicated for hilar lesions and carries seeding risk; repeat ERCP with cholangioscopy (D) could obtain a tissue diagnosis but is less appropriate when the patient already meets protocol criteria and any instrumentation may risk peritoneal seeding; serial stenting (E) ignores malignancy. The only logical flaw is the answer explanation’s claim that PET SUV >5.0 alone fulfills protocol criteria, which is not part of the formal guidelines; this overstatement is a minor medical accuracy issue. A single clarifying addition to the stem—stating that the patient has been deemed a transplant candidate—would eliminate any ambiguity and make choice C unequivocally the best answer.", "medical_accuracy_score": 3, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251219T221819110Z_deepseek-v3.2_seed133", "question_id": "20251219T221819110Z_deepseek-v3.2_seed133-002", "question": "A 38-year-old woman with paroxysmal nocturnal hemoglobinuria (PNH) on eculizumab for 5 years presents with fatigue and dark urine. Laboratory studies show hemoglobin 7.2 g/dL (baseline 10.5), LDH 850 U/L (baseline 300), haptoglobin <10 mg/dL, and negative direct antiglobulin test. She received her last eculizumab dose 12 days ago. Peripheral blood flow cytometry shows 95% PNH clone size (granulocytes). Complement C5 level is undetectable. Which of the following is the most likely explanation for her breakthrough hemolysis?", "options": ["Development of anti-eculizumab antibodies causing drug neutralization", "C5 gene polymorphism (c.2654G→A) resulting in eculizumab-resistant C5", "Concurrent mycoplasma pneumoniae infection with cold agglutinin production", "Functional deficiency of complement factor H due to acquired mutation", "Proximal complement pathway activation via C3 convertase amplification"], "answer": "B", "answer_index": 1, "explanation": "The c.2654G→A polymorphism in the C5 gene results in a single amino acid change (p.Arg885His) that prevents eculizumab binding while maintaining C5 function, leading to breakthrough hemolysis despite adequate drug levels. This autosomal dominant mutation affects approximately 3-4% of Japanese patients and requires switching to ravulizumab or other anti-C5 agents. Anti-drug antibodies are rare with eculizumab. Mycoplasma would cause cold agglutinin disease with positive DAT. Factor H deficiency causes atypical HUS, not PNH exacerbation.", "generator_model": "deepseek-v3.2", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: C (Contradiction) with secondary U. Verdict: Keyed answer B is the intended best answer but the item contains an internal inconsistency. Key clues: breakthrough hemolysis on eculizumab, undetectable C5 level, negative DAT, 95% PNH clone, last dose 12 days ago. The C5 polymorphism (p.Arg885His) is a recognized cause of eculizumab resistance requiring alternative anti-C5 therapy. However, the polymorphism yields a functional C5 variant that is detectable by standard antigenic and functional assays; stating 'C5 level is undetectable' directly contradicts this mechanism and confounds the discriminating feature. Options C and D are clearly incorrect based on negative DAT and disease mechanism; E is implausible with terminal pathway blockade; A is rare and less likely than B. The item remains solvable because B is the most defensible choice among options, but the contradiction requires examinees to ignore the lab inconsistency. Fix: Replace 'Complement C5 level is undetectable' with 'Complement C5 functional activity is present despite therapeutic eculizumab levels' to accurately reflect polymorphic C5 escape.\",\"medical_accuracy_score\":   \t\"4\",\"logical_validity\": false,\"logical_false_reason\": \"C\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: C (Contradiction) with secondary U. Verdict: Keyed answer B is the intended best answer but the item contains an internal inconsistency. Key clues: breakthrough hemolysis on eculizumab, undetectable C5 level, negative DAT, 95% PNH clone, last dose 12 days ago. The C5 polymorphism (p.Arg885His) is a recognized cause of eculizumab resistance requiring alternative anti-C5 therapy. However, the polymorphism yields a functional C5 variant that is detectable by standard antigenic and functional assays; stating 'C5 level is undetectable' directly contradicts this mechanism and confounds the discriminating feature. Options C and D are clearly incorrect based on negative DAT and disease mechanism; E is implausible with terminal pathway blockade; A is rare and less likely than B. The item remains solvable because B is the most defensible choice among options, but the contradiction requires examinees to ignore the lab inconsistency. Fix: Replace 'Complement C5 level is undetectable' with 'Complement C5 functional activity is present despite therapeutic eculizumab levels' to accurately reflect polymorphic C5 escape.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251219T221819110Z_deepseek-v3.2_seed133", "question_id": "20251219T221819110Z_deepseek-v3.2_seed133-003", "question": "A 67-year-old man who underwent orthotopic liver transplantation 4 months ago for HCV cirrhosis presents with fever, cough, and hypoxemia. He is on tacrolimus and prednisone 5 mg daily. Chest CT shows multiple nodular opacities with surrounding ground-glass halos. Bronchoalveolar lavage PCR is positive for Torque teno virus (TTV) DNA at 10^8 copies/mL. Blood TTV viral load is 10^7 copies/mL. Which of the following is the most appropriate interpretation and management?", "options": ["TTV indicates severe immunosuppression; reduce tacrolimus dose and monitor for resolution", "TTV is a direct pulmonary pathogen; initiate intravenous ribavirin therapy", "TTV reactivation suggests CMV co-infection; start ganciclovir empirically", "TTV viral load has no clinical significance in this setting; pursue alternative diagnoses", "TTV indicates possible donor-derived infection; perform lung biopsy for histopathology"], "answer": "A", "answer_index": 0, "explanation": "Torque teno virus (TTV) viral load serves as a functional biomarker of overall immunosuppression in transplant recipients, with high levels indicating excessive immunosuppression and increased risk of opportunistic infections. The radiographic findings suggest invasive fungal infection (e.g., aspergillosis) in an over-immunosuppressed host. Reducing immunosuppression while evaluating for fungal pathogens is appropriate. TTV itself is not a pulmonary pathogen. There is no established antiviral therapy for TTV, and it does not specifically indicate CMV co-infection or donor-derived infection.", "generator_model": "deepseek-v3.2", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V – Verdict: Correct best answer within item logic. Key stem clues: 4-month post-liver transplant on tacrolimus/prednisone; CT halo sign suggesting invasive fungal infection; high TTV DNA in BAL and blood. The item posits TTV viral load as a functional immunosuppression biomarker; Option A fits this premise by recommending tacrolimus reduction while evaluating for fungal pathogens. Alternatives are clearly inferior: B mischaracterizes TTV as a pulmonary pathogen; C fabricates CMV co-infection link; D overstates insignificance while ignoring concerning CT findings; E misattributes donor-derived infection. Logical structure is sound: single best answer exists, key matches, no contradictions, options permit discrimination. Medical accuracy issue: TTV is not an established clinical biomarker for guiding immunosuppression in practice; presenting this as validated standard care misleads learners. The stem also omits standard fungal diagnostic workup that the rationale assumes. Minimal fix: Replace TTV data with a validated immunosuppression marker (e.g., absolute lymphocyte count <500/µL) or explicitly frame TTV as research-based and provide galactomannan results.\",\"medical_accuracy_score\":   \"2\",\"logical_validity\": true,\"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V – Verdict: Correct best answer within item logic. Key stem clues: 4-month post-liver transplant on tacrolimus/prednisone; CT halo sign suggesting invasive fungal infection; high TTV DNA in BAL and blood. The item posits TTV viral load as a functional immunosuppression biomarker; Option A fits this premise by recommending tacrolimus reduction while evaluating for fungal pathogens. Alternatives are clearly inferior: B mischaracterizes TTV as a pulmonary pathogen; C fabricates CMV co-infection link; D overstates insignificance while ignoring concerning CT findings; E misattributes donor-derived infection. Logical structure is sound: single best answer exists, key matches, no contradictions, options permit discrimination. Medical accuracy issue: TTV is not an established clinical biomarker for guiding immunosuppression in practice; presenting this as validated standard care misleads learners. The stem also omits standard fungal diagnostic workup that the rationale assumes. Minimal fix: Replace TTV data with a validated immunosuppression marker (e.g., absolute lymphocyte count <500/µL) or explicitly frame TTV as research-based and provide galactomannan results.", "medical_accuracy_score": 2, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251219T221819110Z_deepseek-v3.2_seed133", "question_id": "20251219T221819110Z_deepseek-v3.2_seed133-004", "question": "A 44-year-old woman with autoimmune hepatitis-primary biliary cholangitis overlap syndrome on ursodeoxycholic acid and budesonide develops recurrent episodes of severe, cramping abdominal pain with diarrhea occurring 30-60 minutes after meals. Symptoms improve with fasting. CT angiography shows no mesenteric ischemia. Gastric emptying study is normal. Upper endoscopy with duodenal biopsies shows villous blunting and intraepithelial lymphocytes. Serum tryptase during an episode is 45 ng/mL (normal <11.4). Which of the following is the most likely diagnosis?", "options": ["Mesenteric venous thrombosis with portal hypertensive enteropathy", "Systemic mastocytosis with gastrointestinal involvement", "Celiac disease with refractory sprue", "Abdominal angina from median arcuate ligament syndrome", "Bile acid malabsorption due to ileal dysfunction"], "answer": "B", "answer_index": 1, "explanation": "Systemic mastocytosis can present with postprandial abdominal pain, diarrhea, and flushing due to mast cell mediator release triggered by food. Elevated serum tryptase (>20 ng/mL) during symptoms is diagnostic. The duodenal findings represent mast cell infiltration rather than celiac disease. Mesenteric ischemia was ruled out by CT angiography. Median arcuate ligament syndrome causes epigastric pain but not diarrhea or elevated tryptase. Bile acid malabsorption does not explain the elevated tryptase or timing of symptoms.", "generator_model": "deepseek-v3.2", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: C (Contradiction). Verdict: No defensible answer. The stem presents mutually exclusive findings: duodenal biopsies show villous blunting and intraepithelial lymphocytes (classic celiac disease), yet the keyed answer is systemic mastocytosis. Mastocytosis demonstrates increased mast cells on biopsy, not villous blunting. While elevated tryptase (45 ng/mL) and acute postprandial symptoms fit mastocytosis, the histology directly contradicts this diagnosis. Celiac disease (C) explains the histology but cannot account for the marked tryptase elevation. This internal inconsistency makes the item unsolvable without violating medical facts. Options A and D are appropriately excluded by imaging; E fails to explain tryptase. The rationale's claim that these histologic findings 'represent mast cell infiltration' is factually incorrect and misleading. Medical accuracy is compromised by this fundamental misinterpretation of biopsy findings. Minimal fix: Replace duodenal biopsy description with 'increased mast cells on CD117 immunostaining' to align with mastocytosis.\",\"medical_accuracy_score\":   \"2\",\"logical_validity\": false,\"logical_false_reason\": \"C\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: C (Contradiction). Verdict: No defensible answer. The stem presents mutually exclusive findings: duodenal biopsies show villous blunting and intraepithelial lymphocytes (classic celiac disease), yet the keyed answer is systemic mastocytosis. Mastocytosis demonstrates increased mast cells on biopsy, not villous blunting. While elevated tryptase (45 ng/mL) and acute postprandial symptoms fit mastocytosis, the histology directly contradicts this diagnosis. Celiac disease (C) explains the histology but cannot account for the marked tryptase elevation. This internal inconsistency makes the item unsolvable without violating medical facts. Options A and D are appropriately excluded by imaging; E fails to explain tryptase. The rationale's claim that these histologic findings 'represent mast cell infiltration' is factually incorrect and misleading. Medical accuracy is compromised by this fundamental misinterpretation of biopsy findings. Minimal fix: Replace duodenal biopsy description with 'increased mast cells on CD117 immunostaining' to align with mastocytosis.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251219T221819110Z_deepseek-v3.2_seed133", "question_id": "20251219T221819110Z_deepseek-v3.2_seed133-005", "question": "A 62-year-old man with essential thrombocythemia (JAK2 V617F-positive) on hydroxyurea presents with acute onset of severe headache and right hemiparesis. CT head shows left middle cerebral artery territory infarction. Platelet count is 450,000/μL. MRI brain with contrast reveals multiple small enhancing lesions in both cerebral hemispheres. Transthoracic echocardiogram shows no vegetations. Blood cultures are negative. Which of the following is the most likely underlying mechanism for his stroke?", "options": ["Nonbacterial thrombotic endocarditis from hypercoagulable state", "Leukoencephalopathy from hydroxyurea toxicity", "Transformation to acute myeloid leukemia with CNS involvement", "Cerebral vasculitis secondary to JAK2 mutation", "Paradoxical embolism through patent foramen ovale"], "answer": "A", "answer_index": 0, "explanation": "Myeloproliferative neoplasms, particularly essential thrombocythemia, can cause nonbacterial thrombotic endocarditis (NBTE) with sterile vegetations that embolize to cerebral arteries. The multiple enhancing brain lesions represent septic emboli analogs from NBTE. Hydroxyurea leukoencephalopathy causes symmetric white matter changes without enhancing lesions. AML transformation would show blasts in blood or marrow. Cerebral vasculitis is not associated with JAK2 mutations. Paradoxical embolism would not explain multiple enhancing lesions without a venous source.", "generator_model": "deepseek-v3.2", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity: V. Verdict: Correct best answer. Key stem clues driving the answer: JAK2-positive essential thrombocythemia (hypercoagulable MPN), acute MCA infarct, multiple bilateral enhancing lesions, and negative infectious workup (blood cultures, TTE). NBTE (Option A) is the most defensible mechanism—sterile vegetations in hypercoagulable states embolize to cerebral arteries. The negative TTE is not contradictory; NBTE vegetations are small and frequently missed on TTE, requiring TEE for detection—a minor limitation but exam-acceptable. Alternative options are clearly inferior: hydroxyurea toxicity (B) produces symmetric non-enhancing leukoencephalopathy; AML transformation (C) would show circulating blasts; JAK2-associated vasculitis (D) lacks evidence; paradoxical embolism (E) cannot explain multiple enhancing lesions without venous source. Medical accuracy is sound: MPNs are established NBTE risk factors. Minor issues: platelet count of 450,000/μL is borderline low for ET, and omitting TEE mention slightly underspecifies the diagnostic approach. Minimal fix: Increase platelet count to >600,000/μL and add 'TEE may be needed to visualize vegetations' to the stem.\",\n\"medical_accuracy_score\":   \"4\",\n\"logical_validity\": true,\n\"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V. Verdict: Correct best answer. Key stem clues driving the answer: JAK2-positive essential thrombocythemia (hypercoagulable MPN), acute MCA infarct, multiple bilateral enhancing lesions, and negative infectious workup (blood cultures, TTE). NBTE (Option A) is the most defensible mechanism—sterile vegetations in hypercoagulable states embolize to cerebral arteries. The negative TTE is not contradictory; NBTE vegetations are small and frequently missed on TTE, requiring TEE for detection—a minor limitation but exam-acceptable. Alternative options are clearly inferior: hydroxyurea toxicity (B) produces symmetric non-enhancing leukoencephalopathy; AML transformation (C) would show circulating blasts; JAK2-associated vasculitis (D) lacks evidence; paradoxical embolism (E) cannot explain multiple enhancing lesions without venous source. Medical accuracy is sound: MPNs are established NBTE risk factors. Minor issues: platelet count of 450,000/μL is borderline low for ET, and omitting TEE mention slightly underspecifies the diagnostic approach. Minimal fix: Increase platelet count to >600,000/μL and add 'TEE may be needed to visualize vegetations' to the stem.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251219T221819110Z_deepseek-v3.2_seed133", "question_id": "20251219T221819110Z_deepseek-v3.2_seed133-006", "question": "A 31-year-old hematopoietic stem cell transplant recipient (day +45) for AML develops new-onset confusion and myoclonus. MRI brain shows symmetric T2 hyperintensities in the thalami and periaqueductal gray matter. CSF shows 5 WBCs/μL, protein 65 mg/dL, glucose 60 mg/dL (serum 95 mg/dL). CSF PCR for HSV, VZV, EBV, CMV, and HHV-6 are negative. Metagenomic next-generation sequencing of CSF detects Astrovirus VA1/HMO-C RNA. Which of the following is the most appropriate management?", "options": ["Intravenous immunoglobulin 2 g/kg divided over 2-5 days", "Oral nitazoxanide 500 mg twice daily for 14 days", "Reduce immunosuppression and provide supportive care", "Intravenous ribavirin loading dose 33 mg/kg then 16 mg/kg every 6 hours", "Intrathecal administration of foscarnet 40 mg twice weekly"], "answer": "C", "answer_index": 2, "explanation": "Astrovirus VA1/HMO-C encephalitis in immunocompromised hosts has no proven antiviral therapy. Reduction of immunosuppression to allow immune reconstitution is the mainstay of management, along with supportive care. Intravenous immunoglobulin has been used but lacks proven efficacy. Nitazoxanide has in vitro activity but no clinical data in CNS infections. Ribavirin has poor CNS penetration and no proven benefit. Intrathecal foscarnet is used for HSV/VZV encephalitis but not for astrovirus.", "generator_model": "deepseek-v3.2", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V (Valid). Verdict on keyed answer: Correct best. Key stem clues: HSCT recipient day +45 (profound T-cell deficiency), new-onset confusion and myoclonus, characteristic symmetric T2 hyperintensities in thalami and periaqueductal gray matter, CSF with mild lymphocytic pleocytosis (5 WBCs), elevated protein (65 mg/dL), normal glucose, negative PCR for all common herpesviruses, and definitive metagenomic NGS detection of Astrovirus VA1/HMO-C RNA. This constellation is pathognomonic for astrovirus encephalitis in immunocompromised hosts. Main logical issue: None. The stem provides complete, non-contradictory information that uniquely supports option C. Main medical accuracy issue: None. The answer correctly reflects that no proven antiviral therapy exists; immune reconstitution via immunosuppression reduction plus supportive care is the standard-of-care mainstay. Alternative options are appropriately excluded: IVIG lacks proven efficacy; nitazoxanide has only in vitro activity without clinical CNS data; ribavirin has poor CNS penetration and no proven benefit; intrathecal foscarnet is indicated for HSV/VZV, not astrovirus. Minimal fix: None required. The item is board-exam ready with accurate, high-yield content.\",\"medical_accuracy_score\":   \t\"5\",\"logical_validity\": true,\"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V (Valid). Verdict on keyed answer: Correct best. Key stem clues: HSCT recipient day +45 (profound T-cell deficiency), new-onset confusion and myoclonus, characteristic symmetric T2 hyperintensities in thalami and periaqueductal gray matter, CSF with mild lymphocytic pleocytosis (5 WBCs), elevated protein (65 mg/dL), normal glucose, negative PCR for all common herpesviruses, and definitive metagenomic NGS detection of Astrovirus VA1/HMO-C RNA. This constellation is pathognomonic for astrovirus encephalitis in immunocompromised hosts. Main logical issue: None. The stem provides complete, non-contradictory information that uniquely supports option C. Main medical accuracy issue: None. The answer correctly reflects that no proven antiviral therapy exists; immune reconstitution via immunosuppression reduction plus supportive care is the standard-of-care mainstay. Alternative options are appropriately excluded: IVIG lacks proven efficacy; nitazoxanide has only in vitro activity without clinical CNS data; ribavirin has poor CNS penetration and no proven benefit; intrathecal foscarnet is indicated for HSV/VZV, not astrovirus. Minimal fix: None required. The item is board-exam ready with accurate, high-yield content.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]